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Metformin in polycystic ovary syndrome: systematic review
and meta-analysis
Jonathan M Lord, Ingrid H K Flight, Robert J Norman
Abstract
Objective To assess the effectiveness of metformin in
improving clinical and biochemical features of
polycystic ovary syndrome.
Design Systematic review and meta-analysis.
Data sources Randomised controlled trials that
investigated the effect of metformin compared with
either placebo or no treatment, or compared with an
ovulation induction agent.
Selection of studies 13 trials were included for
analysis, including 543 women with polycystic ovary
syndrome that was defined by using biochemical or
ultrasound evidence.
Main outcome measure Pregnancy and ovulation
rates. Secondary outcomes of clinical and biochemical
features of polycystic ovary syndrome.
Results Meta-analysis showed that metformin is
effective in achieving ovulation in women with
polycystic ovary syndrome, with odds ratios of 3.88
(95% confidence interval 2.25 to 6.69) for metformin
compared with placebo and 4.41 (2.37 to 8.22) for
metformin and clomifene compared with clomifene
alone. An analysis of pregnancy rates shows a
significant treatment effect for metformin and
clomifene (odds ratio 4.40, 1.96 to 9.85). Metformin
has an effect in reducing fasting insulin
concentrations, blood pressure, and low density
lipoprotein cholesterol. We found no evidence of any
effect on body mass index or waist:hip ratio.
Metformin was associated with a higher incidence of
nausea, vomiting, and other gastrointestinal
disturbance.
Conclusions Metformin is an effective treatment for
anovulation in women with polycystic ovary
syndrome. Its choice as a first line agent seems
justified, and there is some evidence of benefit on
variables of the metabolic syndrome. No data are
available regarding the safety of metformin in long
term use in young women and only limited data on its
safety in early pregnancy. It should be used as an
adjuvant to general lifestyle improvements and not as
a replacement for increased exercise and improved
diet.
Introduction
Polycystic ovary syndrome is characterised by anovula-
tion, infertility, and hyperandrogenism, with clinical
manifestations of irregular menstrual cycles, hirsutism,
and acne. The condition affects an estimated 5-10% of
women of reproductive age,1 2 although this varies
depending on the diagnostic criteria used.3 One of the
commonest presenting complaints of women with
polycystic ovary syndrome is anovulatory infertility.
They also have increased prevalence of cardiovascular
risk factors similar to that seen in the metabolic
syndrome (which, like polycystic ovary syndrome, is
characterised by insulin resistance4). By the age of 40,
up to 40% will have type 2 diabetes or impaired
glucose tolerance.5 Polycystic ovary syndrome is there-
fore an important health concern and may represent a
major health issue affecting young women today.
The use of metformin for women with polycystic
ovary syndrome has aroused a tremendous amount of
interest. Several detailed literature reviews report large
numbers of trials, although most of these are
uncontrolled, have small numbers of participants, and
have no allocation concealment.6–11 This review aims to
answer the question whether metformin is effective in
treating women with polycystic ovary syndrome, by
amalgamating the trials whose methods are of the
highest quality so that meta-analysis can produce valid
results.
Methods
We included randomised controlled trials of met-
formin compared with placebo, no treatment, or
ovulation inducing agents in women with polycystic
ovary syndrome. We included trials only if polycystic
ovary syndrome was defined by using biochemical or
ultrasound evidence. We also included studies of
metformin in conjunction with an ovulation inducing
agent compared with placebo, no treatment, or an ovu-
lation inducing agent.
We searched the trials register of the Cochrane
menstrual disorders and subfertility group in Decem-
ber 2002, the Cochrane central register of controlled
trials (Cochrane Library, Issue 4, 2002), Medline
(January 1966 to December 2002), and Embase (Janu-
ary 1985 to December 2002). We also handsearched
the reference sections of all the randomised controlled
trials obtained.
One reviewer screened the titles and abstracts of
the randomised controlled trials that we identified. Full
text articles were obtained for those trials that fulfilled
the inclusion criteria or for which insufficient
This review is an
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information was given. The methods section was then
sent to another reviewer after all information had been
removed that could identify the authors, the publisher,
or the results of the study. Both reviewers independ-
ently assessed whether the studies met the inclusion
criteria; disagreements were resolved by discussion and
final arbitration by RJN and the Cochrane editorial
base. We sought further information from the authors
where papers contained insufficient information to
make a decision about eligibility or quality.
We performed statistical analyses according to the
statistical guidelines for reviewers in the Cochrane
menstrual disorders and subfertility group. We under-
took sensitivity analyses to examine the stability of the
results in relation to quality of allocation concealment,
blinding, obesity, length of treatment over two months,
dose of metformin, and ethnic group. Data from cross-
over trials were used only from the first phase (before
crossover).
Description of studies
Twenty randomised controlled trials met the initial eli-
gibility criteria. We excluded seven studies, leaving 13
to be included in the analysis, of which 10 were double
blind,12–21 two were single blind,22 23 and one we
presumed to be unblinded.24
The diagnosis of polycystic ovary syndrome
broadly followed the consensus criteria from the
National Institutes of Health of anovulation and
hyperandrogenaemia, with exclusion of other endo-
crinopathies, in all but three trials that used ultrasound
criteria.12 17 24 All of the included trials required
oligomenorrhoea or proved anovulation, and all of




Care is needed in interpreting pregnancy rates as no
trial had pregnancy as a primary outcome measure,
and only six of the trials had tubal disease or male
factor infertility, or both, as exclusion crite-
ria.14 15 17 20 21 24 Six of the nine trials reporting
pregnancy rates were of less than four months’
duration.14 22 17 21 20 12
The clinical pregnancy rate reported by five trials
comparing metformin with placebo did not show
evidence of benefit (odds ratio 2.76, 95% confidence
interval 0.85 to 8.98, P = 0.09).12 14 17 21 22 We found no
significant heterogeneity, but the funnel plot was asym-
metrical, which raised the possibility of publication
bias. In the three trials comparing clomifene with met-
formin compared with clomifene alone, we found a
significant effect for metformin with clomifene (4.40,
1.96 to 9.85, P = 0.0003).14 15 24 We detected no
heterogeneity.
Ovulation rate
Overall, as figure 1 shows, a significant effect of
metformin compared with placebo on ovulation
became obvious (3.88, 2.25 to 6.69, P < 0.0001). We
detected no significant heterogeneity. The funnel plot
was limited as only seven trials were included, but no
bias was evident. The two trials with the lowest weight
(total weight 11.8%) are the two that did not show a
significant effect.
Figure 2 shows that the effect for metformin and
clomifene compared with clomifene alone was also
significant (4.41, 2.37 to 8.22, P < 0.0001) based on the
results of three trials. However, we detected significant
heterogeneity. Two of the trials used participants who
were known to have been resistant to clomifene previ-
ously, and consequently the ovulation rate in their pla-
cebo and clomifene arms was relatively low (17.5%).14 15
These two trials showed a significant effect for
metformin and clomifene compared with clomifene
and placebo (9.34, 3.97 to 21.97, P < 0.00001), without
any heterogeneity. In contrast the third trial, where
participants were not selected on the basis of being
resistant to clomifene, had a high ovulation rate in their
placebo and clomifene arm (64%).24 This trial did not
show evidence of benefit for metformin compared
with clomifene in our analysis when odds ratios were
used, although it did in the original report.
Weight
We found no evidence of effect from metformin on
body weight or body mass index. Only one trial
reported waist circumference.18 We found no evidence
of an effect by metformin on waist circumference, nor
on waist:hip ratio, as reported by seven trials with mini-
mal heterogeneity.12 13 14 16 22 18 21
Blood pressure
Two trials comparing metformin with placebo
reported blood pressure.16 22 Analysis showed a signifi-
cant reduction for metformin in both systolic blood
pressure (weighted mean difference − 9.07, 95% confi-
dence interval − 14.98 to − 3.15, P = 0.003) and diasto-
lic blood pressure ( − 5.69, − 9.66 to − 1.73, P = 0.005).
We detected no heterogeneity between the two trials,
but the total number of participants was only 47.
Adverse events
Only one trial reported miscarriage rates and multiple
pregnancy rates.20 Neither reached significance.
Four trials included details about side effects that
are suitable for analysis (fig 3).12 16 17 21 One trial used
metformin for six weeks,12 wheras the others used it for
12 weeks or more. Metformin caused a significantly









Test for heterogeneity: χ2=6.05, df=6, P=0.42





































2.51 (1.01 to 6.25)
9.89 (2.24 to 43.61)
6.89 (1.12 to 42.33)
5.96 (1.74 to 20.38)
1.00 (0.15 to 6.72)
1.26 (0.07 to 21.72)
5.88 (1.13 to 30.61)
3.88 (2.25 to 6.69)
Peto odds ratio
(95% CI fixed)
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(95% fixed)
Comparison: Metformin versus placebo or no treatment (clinical outcomes)
Outcome: Ovulation rate
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3.84, 95% confidence interval 1.07 to 13.81, P = 0.05,)
and other gastrointestinal disturbance (4.40, 1.82 to
10.66, P = 0.003). We detected no heterogeneity in the
results. One trial reported that most of their dropouts
were because of gastrointestinal disturbance.12 No trial
reported any serious adverse events.
Biochemical outcomes
Insulin
Metformin had a significant effect in reducing fasting
insulin concentrations with a weighted mean differ-
ence of − 5.37 ( − 8.11 to − 2.63, P = 0.0001) (fig 4).
Overall nine trials were included in the analysis, and all
Polycystic ovary syndrome and clomifene sensitive
Subtotal (95% CI)
Test for heterogeneity: χ2=0.0, df=0
Test for overall effect: z=0.0 P=1
Polycystic ovary syndrome and clomifene resistant
  Kocak 2002
  Malkawi 2002
Subtotal (95% CI)
Test for heterogeneity: χ2=0.80, df=1 p=0.37
Test for overall effect: z=5.12 P<0.00001
Polycystic ovary syndrome and clomifene sensitivity not defined
  El-Biely 2001
Subtotal (95% CI)
Test for heterogeneity: χ2=0.0, df=0
Test for overall effect: z=1.39 P=0.17
Total (95% CI)
Test for heterogeneity: χ2=7.07, df=2 P=0.029



































12.36 (4.32 to 35.39)
5.41 (1.24 to 23.51)
9.34 (3.97 to 21.97)
1.90 (0.77 to 4.70)
1.90 (0.77 to 4.70)





Comparison: Metformin combined with ovulation induction agent versus ovulation induction agent alone (clinical outcomes)
Outcome: Ovulation rate
Fig 2 Metformin combined with clomifene compared with clomifene alone—ovulation rate
Nausea and vomiting
  Moghetti 2000
  Ng 2001
  Yarali 2002
Subtotal (95% CI)
Test for heterogeneity: χ2=0.02, df=2 P=0.99
Test for overall effect: z=1.93 P=0.05
Gastrointestinal disturbance (other than nausea and vomiting)
  Fleming 2002
  Moghetti 2000
  Ng 2001
Subtotal (95% CI)
Test for heterogeneity: χ2=0.11, df=2 P=0.94





































4.17 (0.61 to 28.62)
4.00 (0.33 to 48.66)
3.19 (0.12 to 84.44)
3.91 (0.98 to 15.64)
4.20 (1.38 to 12.81)
6.58 (0.28 to 153.75)
6.33 (0.26 to 152.87)





Comparison: Metformin versus placebo or no treatment (clinical outcomes)
Outcome: Adverse events (miscarriage, multiple pregnancy, side effects)
Fig 3 Metformin compared with placebo or no treatment—side effects
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had wide confidence intervals.12 13 14 16 17 18 20 21 22 Signifi-
cant heterogeneity was attributable to the large
treatment effect seen in two trials.13 22 When these trials
were excluded, the significance remained without
significant heterogeneity, which implies a genuine
effect of treatment. The funnel plot implies publication
bias, although the symmetry is improved when the two
trials are excluded from the analysis.
Lipids
Effects on serum concentrations of cholesterol and
lipids were reported by three trials with a total of 98
participants. 12 16 17 Total cholesterol showed no
evidence of a significant treatment effect with
metformin, but low density lipoprotein cholesterol was
significantly reduced in the metformin group, with a
weighted mean difference of − 0.44 ( − 0.79 to − 0.08,
P = 0.02). We detected no significant heterogeneity,
although none of the trials showed a significant
treatment effect of their own. We found no evidence of
an effect on high density lipoprotein cholesterol from
metformin. We also found no evidence of an effect on
triglyceride concentrations.
Discussion
Metformin is effective in achieving ovulation in women
with polycystic ovary syndrome. Meta-analysis is valid
only if the included participants of all the different
studies represent the same overall population. We
included only studies of women who have clearly
defined polycystic ovary syndrome. The baseline char-
acteristics of the participants from all the trials are
similar and represent a population of women with
hyperandrogenic anovulation who are mostly over-
weight and have insulin resistance. We believe that this
population is well recognised worldwide and that the
results of this meta-analysis are applicable to this whole
group of women. We found a reasonable number of
trials with good methods, and we found no evidence of
significant publication bias.
Limitations
This review has some limitations. Differences between
trial populations have resulted in heterogeneity in
some of the analyses as discussed above. Several of the
results are constrained by small numbers and wide
standard deviations, which limits confidence in
drawing conclusions. Although sensitivity analyses
using various variables did not alter the conclusions
fundamentally, some of the planned analyses were
constrained owing to the limited number of trials avail-
able. Another concern is that the trials were of varying
duration, and meta-analysis will imply that treatment
effect is similar in all trials whatever their length of
treatment and follow up. However, metformin has its
effect relatively quickly,13 20–23 and analysis shows no
correlation between length of trial and proportion
ovulating with metformin alone among the included
trials (r= 0.39, P = 0.39). Conversely the correlation
between trial length and proportion ovulating with
placebo is significant (r= 0.83, P = 0.02), and analysis of
trials of varying length will therefore tend to produce a
conservative estimate of the treatment effect for
metformin compared with placebo.
Strengths
The meta-analysis shows that metformin is effective in
achieving ovulation in women with polycystic ovary
syndrome. Ovulation was achieved in 46% of those
who received metformin alone (compared with 24%
who received placebo), with a number needed to treat
(NNT) of 4.4. Where metformin and clomifene were
compared with clomifene alone, ovulation occurred in
76% of women receiving metformin and clomifene,
compared with 42% of those receiving clomifene
alone. The number needed to treat is 3.0, with a range
of 1.6 in the trial with the lowest rate of ovulation with
clomifene alone (the participants were selected as
having been previously resistant to clomifene) to 8.6 in
a trial in which the participants’ previous sensitivity to
clomifene was unknown.
These data seem robust with no evidence of major
publication bias. Although the combination of
metformin with clomifene results in higher ovulation
rates, analysis is robust only in those participants who
were known to be resistant to clomifene previously.
Other reviews have described ovulation rates of
40-85% with clomifene alone, although resistance to
  Fleming 2002
  Jakubowicz 2001
  Kocak 2002
  Moghetti 2000
  Nestler 1996
  Ng 2001
  Pasquali 2000
  Vandermolen 2001
  Yarali 2002
Total (95% CI)
Test for heterogeneity: χ2=33.00, df=8 P=0.0001

































































-1.60 (-7.09 to 3.89)
   -32.84 (-46.38 to -19.30)
    -1.00 (-16.55 to 14.55)
 -11.10 (-19.88 to -2.32)
   -22.00 (-32.55 to -11.45)
-2.20 (-6.62 to 2.22)
     2.60 (-19.16 to 24.36)
  -4.00 (-13.20 to 5.20)
    4.20 (12.19 to 20.59)





Comparison: Metformin versus placebo or no treatment (biochemical outcomes)
Outcome: Fasting insulin (m IU/l)
Fig 4 Metformin compared with placebo or no treatment—fasting insulin
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clomifene is more prevalent in women who are
overweight, which is a common situation in women
with polycystic ovary syndrome.25 26 A known adverse
effect of clomifene alone is an increase in rates of
multiple pregnancies,27 but as yet no data imply that
this also applies to the combination of metformin with
clomifene.
Pregnancy rates are harder to interpret in the
meta-analysis, and no trial had live birth rate as a
defined outcome measure.We found evidence of effect
for metformin with clomifene, but few trials had preg-
nancy as a defined outcome measure, few controlled
for other causes of infertility, and the possibility of
publication bias limits confidence in this analysis.
Possible recommendations
Polycystic ovary syndrome is known to be character-
ised by insulin resistance. Insulin resistance is thought
to be a key factor in the development of the metabolic
syndrome that is associated with an increased risk of
cardiovascular disease.28 If metformin were to improve
the variables associated with the metabolic syndrome
in women with polycystic ovary syndrome, then in
theory it might be expected to reduce the risk of
adverse cardiovascular events. If this were to be true
then clinically it would be logical to use metformin as a
first line agent. The meta-analysis confirms that
metformin does significantly reduce fasting insulin and
therefore by implication insulin resistance.
Other reported variables of the metabolic syn-
drome include blood pressure and concentrations of
cholesterol and triglycerides. Interpretation of blood
pressure is limited by having only 47 participants to
analyse, but systolic and diastolic blood pressure were
significantly reduced by metformin. Total concentra-
tions of cholesterol, high density lipoprotein choles-
terol and triglycerides were all unaffected by met-
formin, but we found a significant if small reduction in
low density lipoprotein cholesterol on the basis of data
from 97 participants. Although modest, we believe that
these benefits in variables known to be associated with
adverse cardiovascular risk are further evidence to jus-
tify recommending the use of metformin as a first line
treatment for anovulation in women with polycystic
ovary syndrome.
Contraindications
Metformin was associated with side effects in the form
of nausea, vomiting, and gastrointestinal disturbance.
Although no serious adverse events were reported,
these side effects limited participation levels in some
trials. We found no literature about the safety of long
term use of metformin in young women, and no
conclusion can be drawn from this review as the long-
est trial followed up participants for only six months.
Metformin is contraindicated in the presence of even
mild renal impairment because of a danger of lactic
acidosis, and it is associated with decreased absorption
of vitamin B12. Experience of metformin in pregnancy
has been limited, and, although there is currently no
evidence that it is teratogenic,29 caution is necessary
until its safety in the first trimester has been evaluated
more fully.
The overall ovulation rate achieved by metformin
or metformin and clomifene was 57%. Other studies
have shown greater ovulation rates with lifestyle
improvements that included increased exercise and
General advice before conception31
For example, folate, smoking, rubella
Lifestyle advice32
Diet, exercise, weight loss
If diet and exercise regimes are not
effective, and renal function is normal
Start metformin after meals, increasing dose
stepwise up to 500 mg three times daily.
Consider 1 g twice daily if tolerated33
If effective continue treatment for 6
months to 1 year.
If not effective add clomifene and
follow local policies for monitoring34
Pregnancy
 Stop metformin immediately
(more data are needed on
the effect of metformin in early










Fig 5 Suggested algorithm for the management of ovulation
induction in women with polycystic ovary syndrome
What is already known on this topic
Polycystic ovary syndrome is characterised by
insulin resistance and worsened by obesity
Many trials have reported the use of metformin in
polycystic ovary syndrome, but most are
observational and involve small numbers of
participants
Previous reviews have reached different
conclusions about the effectiveness of metformin
in treating polycystic ovary syndrome
What this study adds
This is the first systematic review and
meta-analysis of randomised controlled trials in
the use of metformin in treating polycystic ovary
syndrome
Where metformin is used as a sole agent,
ovulation is achieved in 46% of recipients
compared with 24% in the placebo arm
(NNT= 4.4)
Where metformin and clomifene are used in
combination, 76% of recipients ovulate compared
with 42% receiving clomifene alone (NNT= 3.0)
Metformin has small but beneficial effects on
aspects of the metabolic syndrome
There is no evidence that metformin causes
weight loss
Equal or better ovulation rates than those
achieved by metformin have been described by
using lifestyle interventions to achieve weight loss
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weight loss.30 We found no evidence that metformin
has an effect on either reducing body mass index or
altering the waist:hip ratio. Patients need to be aware
that it is not a “weight loss” drug. Metformin should
therefore always be used as an adjuvant to general life-
style improvements and not as a replacement for
increased exercise and improved diet. Figure 5 gives
suggestions on how to induce ovulation in women with
polycystic ovary syndrome.31–35
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